This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.
High throughput sequencing for in depth analysis of pre-treatment HIV-1 drug resistance in Sweden, Andersson E, Ambikan A, Brännström J, Aralaguppe S, Yilmaz A, Albert J, Neogi U, Sönnerborg A. Poster presentation at 6th Nordic HIV and Hepatitis Conference, 25th to 27th of September 2019, Stockholm, Sweden
Prevalence and spatiotemporal dynamics of the HIV-1 circulating recombinant form 03_AB (CRF03_AB) in the former Soviet Union, Ozhmegova E, Lebedev A, Pasechnik O, Blokh A, Grezina L, Dementeva N, Sandyreva T, Kazennova E and Bobkova M, Poster presented at the 18th European meeting on HIV and hepatitis, 29-31 October 2020
The efficacy of first-line therapy based on RPV in HIV-infected patients with pre-existing E138A mutation in reverse transcriptase, Kuznetsova A., Gromov K. , Kazennova E., Bobkova M. Maurizio Zazzi, Francesca Incardona, Anders Sönnerborg, Poster presented at the 18th European meeting on HIV and hepatitis, 29-31 October 2020
Analysis of the local HIV-1 epidemic in Vologda Region, Russia: predominance of CRF03_AB and rapid expansion of URFs
Ozhmegova E, Lebedev A, Krylova T, Kirillova I, Dementeva N, Kazennova E, Bobkova M.
Poster presentation at 17th European AIDS Conference (EACS European AIDS Clinical Society, Basel, November 6-9, 2019).
Susceptibility to HIV - integrase inhibitors in HIV-1 sub subtype A6 isolates
Giannini A, Giammarino F, Antonova A, Ozhmegova E, Kaiser R, Dragoni F, Boccuto A, Vicenti I, Sönnerborg A, Bobkova M, Zazzi M, Saladini F, Poster to be presented at the ICAR Conference, 12-16 October 2020, accepted among the poster session "Best of Posters" at the virtual 18th European Meeting on HIV & Hepatitis, October 28-30, 2020